Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of PHAT: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders7984+5
Shares24.9M25.5M+623.2K (+2.5%)
Value$843.6M$819.8M−$23.7M (−2.8%)

New holders (13)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to PHAT in Q3 2021
InstitutionSharesValue% of portfolio
StepStone Group LP422,085$13.5M0.88%
Great Point Partners LLC220,863$7.09M1.68%
FMR LLC154,200$4.95M0.00%
Dimensional Fund Advisors LP39,374$1.26M0.00%
Woodline Partners LP29,903$960.0K0.02%
Martingale Asset Management L P19,908$640.0K0.01%
Parametric Portfolio Associates LLC13,640$438.0K0.00%
SG Americas Securities, LLC8,420$270.0K0.00%
UBS Asset Management Americas Inc7,514$241.2K0.00%
Goldman Sachs Group Inc7,163$230.0K0.00%
Quantbot Technologies LP1,000$32.0K0.00%
Captrust Financial Advisors25$1.00K0.00%
Berman Capital Advisors, LLC9$00.00%

Sold out (8)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of PHAT in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Greenspring Associates, LLC415,277$14.1M
Marshall Wace North America L.P.34,436$1.17M
Marshall Wace, LLP29,731$1.01M
Cambridge Investment Research Advisors, Inc.16,300$552.0K
Engineers Gate Manager LP14,310$484.0K
Amundi4,513$153.0K
Leonteq Securities AG1,500$50.8K
UBS Group AG699$24.0K